“Ensuring equitable access to these effective but high-cost medications, and supporting individuals so that they can stay on the therapy long-term, should be a priority for our clinicians and policymakers." said corresponding author Dhruv S. Kazi, MD, MS,
www.bidmc.org/about-bidmc/...
bidmc.org
More Than Half of U.S. Adults Could Benefit from GLP-1 Medications, Researchers Find | BIDMC of Boston
BIDMC researchers find that 137 million adults are eligible for semagludtide for weight loss, diabetes management or recurrent cardiovascular event prevention.